Page 367 - TBE_Book_V2_2019

Chapter 12b: TBE in Poland

Table 2: TBE reporting and vaccine prevention in Poland
ONLY cases of neuroinfection
Case definition—per ECDC (2.44) 19

Clinical Criteria: Any person with symptoms of inflammation of the central nervous
system (CNS): e.g. meningitis, meningoencephalitis, encephalomyelitis, encephalo-
radiculitis.

Laboratory Criteria: Laboratory criteria for case confirmation
At least 1 of the following 5 criteria:
 TBE-specific IgM AND IgG antibodies in blood
 TBE-specific IgM antibodies in cerebrospinal fluid (CSF)
 Seroconversion or 4-fold increase of TBE-specific antibodies in paired serum samples
 Detection of TBE viral nucleic acid in a clinical specimen
Mandatory TBE  Isolation of TBEV from clinical specimen
reporting
Laboratory criteria for a probable case:
 Detection of TBE-specific IgM-antibodies in a unique serum sample
 Serological results should be interpreted according to the vaccination status and
previous exposure to other flaviviral infections. Confirmed cases in such situations
should be validated by serum neutralization assay or other equivalent assays

Epidemiological Criteria: Exposure to a common source (unpasteurized dairy products)

Case Classification
 Probable case: Any person meeting the clinical and laboratory criteria for a probable
case; any person meeting the clinical criteria and with an epidemiological link
 Confirmed case: Any person meeting the clinical and laboratory criteria for case
confirmation
Other TBE Obligatory reporting by diagnostic laboratory of any positive results from serological (IgM)
surveillance examination to local health service in the patient’s place of residence
Special clinical Contact with ticks; consumption of non-pasteurized dairy products 14,15
13
features Mortality 0.5-2.8%
Since 1993:
 FSME-Immun (manufacturer: Pfizer) in 2 formulations
Available vaccines (adults and children <16 years of age)
 Encepur (manufacturer: GSK) in 2 formulations
(for adults and children 1-11 years of age).
Vaccination Recommendation for additional supplementary immunization – 1970s.
recommendations No reimbursement*
and reimbursement
Vaccine uptake by
age group/risk 18
group/general In 2015, 27,849 persons; among them 11,516 who are <20 years of age
population
Name, address/ Lack of Reference Laboratory or Center – since 2004
website of TBE NRC (due to more stable/constant disease situation)
*In Poland, vaccination against TBE is recommended (but not financed from the budget of the Ministry of Health) for persons
in areas with severe occurrence of the disease, in particular: forest workers, foragers (e.g. persons who harvest mushrooms,
berries, etc – commercially or recreationally), stationed military, guards brigade and border, farmers, young people in practice
(outdoor play and recreation), tourists and visitors to camps and colonies.

362